Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

(Reuters) -Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...